2015
CA‐074Me compound inhibits osteoclastogenesis via suppression of the NFATc1 and c‐FOS signaling pathways
Patel N, Nizami S, Song L, Mikami M, Hsu A, Hickernell T, Chandhanayingyong C, Rho S, Compton JT, Caldwell J, Kaiser PB, Bai H, Lee HG, Fischer CR, Lee FY. CA‐074Me compound inhibits osteoclastogenesis via suppression of the NFATc1 and c‐FOS signaling pathways. Journal Of Orthopaedic Research® 2015, 33: 1474-1486. PMID: 25428830, DOI: 10.1002/jor.22795.Peer-Reviewed Original ResearchConceptsOsteolytic disordersOsteoclast biologyBone resorptionCA-074MeC-FOSMechanisms of cathepsinsCathepsin B knockout miceB knockout miceCathepsin B inhibitor CA-074Dose-dependent mannerOsteoclast resorption pitsCathepsin B inhibitionInhibits osteoclastogenesisNFATc1 pathwayNew therapiesOsteoclastogenic effectsCA-074Knockout miceLysosomal proteasesMature osteoclastsResorption pitsCathepsin KNew targetsOsteoclastsCompound inhibits
2009
Zoledronate reduces unwanted bone resorption in intercalary bone allografts
Seo SW, Cho SK, Storer SK, Lee FY. Zoledronate reduces unwanted bone resorption in intercalary bone allografts. International Orthopaedics 2009, 34: 599-603. PMID: 19343345, PMCID: PMC2903128, DOI: 10.1007/s00264-009-0748-7.Peer-Reviewed Original ResearchConceptsAllograft resorptionIntercalary allograftsBone resorptionBone allograftControl groupZoledronate solutionIntercalary bone allograftsBone formationBone mineral densitySynthetic pyrophosphate analoguesHigh-dose bisphosphonatesPharmacological modificationGraft incorporationMineral densityBone densityAllograftsIdeal doseResorptionAnimal trialsHistological analysisBisphosphonatesSegmental defectsPyrophosphate analogsExperimental groupRat femur
2004
Bisphosphonates May Reduce Recurrence in Giant Cell Tumor by Inducing Apoptosis
Chang SS, Suratwala SJ, Jung KM, Doppelt JD, Zhang HZ, Blaine TA, Kim TW, Winchester RJ, Lee FY. Bisphosphonates May Reduce Recurrence in Giant Cell Tumor by Inducing Apoptosis. Clinical Orthopaedics And Related Research® 2004, 426: 103-109. PMID: 15346059, DOI: 10.1097/01.blo.0000141372.54456.80.Peer-Reviewed Original ResearchConceptsGiant cell tumorCell tumorsAdjuvant therapyGiant cellsExogenous receptor activatorSpecific adjuvant therapyExtensive bone destructionTumor culturesLocal adjuvant therapyHigh recurrence rateNovel adjuvant therapyOsteoclastlike giant cellsNovel therapeutic agentsNF-kappaB ligandDose-dependent mannerBone destructionRecurrence rateAggressive tumorsBone resorptionSystemic useReceptor activatorAutocrine loopAutocrine mannerTumorsAutocrine regulation